In April 2018, the Pennsylvania Department of Health (DOH) announced that it would expand the state’s Medical Marijuana Program by implementing recommendaitons of the Medical Marijuana Advisory Board to include dry leaf or flower as an allowable form to be sold at dispensaries later this summer. Per DOH, the newly expanded provision will allow dry leaf or flower to be sold in a form that can be vaporized, not smoked. Previously, patients could were only permitted to access concentrates, topicals, and capsules, which, though effective, are often considered more costly forms of treatment.
This change will not only help to drive down the costs of medical marijuana treatment, it will also expand the potential medical marijuana market in Pennsylvania. In states that allow its sale, flower makes up about 55-to-60 percent (link) of medical marijuana sales. The introduction of flower in Pennsylvania will also increase accessibility, as growers will no longer have to go through a lengthy extraction process.
The expanded provision will also make it easier for patients to microdose, which is very helpful in the management of certain conditions such as PTSD and chronic pain. Microdosing (link) with flower is much easier given the lower THC ratios in flower as opposed to concentrates.
For a full list of qualifying conditions – which has been expanded from 17 to 21 serious conditions – click here. (link)